Analysts expect over 2018 decreasing revenue BB Biotech, high dividend yield

Tomorrow BB Biotech will publish its past quarter's results. For this year BB Biotech 's revenue will be around 0 million CHF. This is according to the average of the analysts' estimates. This is rather significant lower than 2016's revenue of 730,05 million CHF.

Historical revenues and results BB Biotech plus estimates 2018

The analysts expect for 2018 a net profit of 444 million CHF. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a profit per share of 8,18 CHF. So the price/earnings-ratio equals 8,12.

Huge dividend BB Biotech

Analysts expect a dividend of 5,37 CHF per share. Thus the dividend yield equals 8,09 percent. The average dividend yield of the biotech companies equals a low 1 percent.

BB Biotech 's market capitalization is based on the number of outstanding shares around 3,68 billion CHF.

At 10.16 the stock trades 0,75 percent lower at 66,4 CHF.

Price data BB Biotech 2007-2018

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.